

ECTO-NOX Proteins

D. James Morré • Dorothy M. Morré

ECTO-NOX Proteins

Growth, Cancer, and Aging

 Springer

D. James Morré
Mor-NuCo, LLC
Purdue Research Park
West Lafayette, IN, USA

Dorothy M. Morré
Mor-NuCo, LLC
Purdue Research Park
West Lafayette, IN, USA

ISBN 978-1-4614-3957-8 ISBN 978-1-4614-3958-5 (eBook)
DOI 10.1007/978-1-4614-3958-5
Springer New York Heidelberg Dordrecht London

Library of Congress Control Number: 2012941093

© Springer Science+Business Media New York 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.


Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Preface

One does not discover new lands without consenting to lose sight of the shore for a very long time.

André Gide



The discovery of the ENOX proteins was inexorably interwoven with the concept of a plasma membrane electron transport first indicated from the findings of Cathy Frantz, a masters student at Purdue University. Cathy found microsomal electron transport activities associated with highly purified plasma membranes from rat livers. The first report of these findings in 1973 at the American Society of Cell Biology meetings was greeted with indifferent disbelief. Clear exceptions were Prof. Fred Crane of Purdue University, a member of Cathy's examining committee and Fred's close friend and colleague, Prof. Hans Löw of the Karolinska Institute in Sweden. The Morrés continued to pursue these observations in their efforts to solidify the flow-differentiation model of Golgi apparatus functioning whereas Fred and Hans set upon a quest to discover the elusive plasma membrane electron transport system. That quest culminated with two co-edited volumes, one on animals in 1990

and one on plants in 1991 entitled *Oxidoreduction at the Plasma Membrane: Relation to Growth and Transport* published by CRC Press (Crane et al. 1990b, 1991). The existence of growth-related NADH oxidases of the plant and animal plasma membrane were first reported in 1986 from plants (Morré et al. 1986a) but it was not until 1990 (Morré and Crane 1990; Fig. 4.8; cover) that their role as the terminal oxidases of the plasma membrane electron transport chain was correctly formulated.

We thank our good friends and colleagues Frederick L. Crane and Hans Löw for championing the concept that the plasma membranes might contain redox active proteins with important functions in growth and disease even in the face of general non-acceptance of that notion by the overall scientific community and a universal lack of enthusiasm by extramural funding agencies for studies of plasma membrane electron transport no matter how well conceived.

It is a singular but sometimes lonely privilege to write a book on a potentially important new family of proteins virtually single handedly identified, cloned, characterized and clinically implemented with minimal independent outside confirmation at the time. While masquerading as intractable proteins, they have and continue to offer remarkable opportunities for research, commercial development and outside confirmation (Chap. 11; Table 11.1). The latter underscores the complexity of these proteins and the many unusual difficulties especially in their assay. We recall a visit from Dr. Warren McKellar of Eli Lilly to our laboratory in the very early days of anti-cancer sulfonylurea research to carry out a spectrophotometric assay on his own to validate the activity. He was pleased to see a rate only to remark a few moments later that it had stopped momentarily only to start up again a few minutes later. Several more years were required before the true meaning of that observation and its subsequent reproduction with other systems finally led to the still controversial conclusion that ENOX activities were oscillatory.

The ENOX proteins were discovered as a result of a search for a growth-related protein at the cell surface that was the target for immobilized forms of the anticancer drug doxorubicin (Adriamycin®). In the late 1970s several groups demonstrated that doxorubicin exhibited an enhanced anti-cancer activity if it was first conjugated to an impermeant support and not permitted to enter the cell (Chap. 11). As doxorubicin is a redox-active quinone site inhibitor, a redox protein was sought that was at the cell surface and cancer-specific. The search led eventually to discovery of the ECTO-NOX (ENOX) family of external hydroquinone oxidases, also capable of oxidizing external NADH. One subset of the ENOX proteins, the tumor-specific tNOX or ENOX2 proteins, was inhibited by doxorubicin and other quinone site-targeted anti-cancer drugs, was cancer-specific, was absent from the surface of non-cancer cells and tissues and was the first ENOX protein to be cloned (Chueh 1997; Chueh et al. 2002b). Three additional family members including the constitutive human ENOX1 in 2008 (Jiang et al. 2008) followed with the most recent, an age-related ENOX protein, cloned in 2010 and a constitutive ENOX1 from plants in 2011. Being proteins of the external cell surface and lacking *trans*-membrane helices to anchor the protein in the membrane, ENOX proteins were found to be shed and to appear in soluble form in patient sera and urine where they serve as early diagnostic markers for cancer presence and

organ site to permit very early intervention strategies prior to advanced disease and metastatic spread (Chap. 12).

Findings of Chap. 8 suggest that the cancer- or tumor-related ENOX2 (tNOX) proteins are all splice variants from a single gene. More importantly, each major type of human cancer is characterized by characteristic transcript variants of unique molecular weight and isoelectric point (Chap. 12). Using a proteomics approach and a recombinant antibody specific for a common exon, it is possible not only to detect cancer but to diagnose it as well.

The purpose of this book is to document this unique family of cell surface proteins (the ECTO-NOX or ENOX protein family) involved in growth, biological time keeping, cancer, aging and viral infections and having properties of prions. The ENOX proteins are the exclusive discovery (subsequently confirmed by others) of the authors, Drs. D. James and Dorothy Morr , and their students and research associates at Purdue University. Roles in plasma membrane electron transport (Chap. 4), growth (Chap. 5), biological time keeping (Chap. 6), cancer (Chaps. 8, 11 and 12), prevention of viral infections (Chap. 7), crop production through control of plant growth (Chap. 10), and coronary artery disease and skin aging (Chap. 9), are among the many developing opportunities for new discovery and commercialization surrounding the ENOX proteins.

The book provides an ENOX-based mechanism for how cells become larger (increase in size) that is both unique and well documented with applications not only to cancer and cancer therapy but for production agriculture as well (Chap. 10) with increase of biomass for biofuel production as one exciting future prospect.

Finally, the concept of and the evidence for oscillations in the ratios of electron spin pairs defining *ortho* and *para* water as the basis for highly coordinated populations of coherent water that appear vital to water's biological and physical properties is completely new, of interest to the biological and physical sciences and now becoming widely accepted by the physical scientists involved with the study of the properties of water (Chap. 6).

Special mention is accorded to Michael Berridge, Frederick Crane, Iris Sun, Rita Barr and Hans L w who have unwaveringly promoted plasma membrane redox and a functional role of ENOX proteins in the overall process, to the late Albert Overhauser for encouragement to seek an explanation of the oscillatory patterns of ENOX proteins at the atomic level (Chap. 6), to Michael B ttger for assistance with pivotal growth measurements (Chap. 5), to Ron Brightmore for his inspiring surveys of the literature and to Profs. Jacob Levitt and Hale Fletchall of the University of Missouri for planting the initial seeds of inquiry. Special thanks to Don Lee, Tom Shelton, Graham Kelly and Richard Greaves for recognizing the commercial potential of the ENOX protein family.

We express our appreciation to the many colleagues, postdoctorals, graduate students, undergraduate assistants, and technicians whose invaluable assistance made possible the experimental studies especially as graduate students, Andrew Brightman, P.-J. Chueh, Chinpal (James) Kim, Xiaoyu Tang and Ziying Jiang for ground breaking protein purification and molecular cloning efforts. Appreciation is extended as well to the even greater numbers who challenged and criticized the work to force us

to work even more diligently to distinguish among possible interpretations of the findings. We thank Peggy Runck for manuscript preparation and Aya Ryuzoji for preparation of the figures. We are especially indebted to the unwavering support of the Morr  children, Connie, Jeffrey and Suzanne, and grandchildren, Christopher, Eric and Katherine Chalko, Matthew, Timothy and Nicholas Miner, Suzanna Morr  and Aren and Mariah Rudder. May our ENOX proteins always oscillate in synchrony.

West Lafayette, IN, USA

D. James Morr 
Dorothy M. Morr 

Contents

1	The ENOX Protein Family	1
1.1	The ENOX Protein Family Members	1
1.2	ENOX Proteins Are Associated with the External Cell Surface as Ecto Proteins and Are Shed into the Environment	4
1.3	Two Activities of ENOX Proteins Alternate	6
1.4	ENOX Proteins Participate Directly in the Enlargement Phase of Cell Growth	7
1.5	ENOX Proteins Are Resistant to Degradation and Tend to Form Insoluble Aggregates	7
1.6	ENOX Proteins Are Dicotoppor Proteins Lacking Both Iron and Flavin	8
1.7	The Oscillatory Behavior Complicates Assays of ENOX Activities	10
1.8	The Distinctive 2+3 Pattern of ENOX Oscillations Is a Unifying Characteristic of All Family Members	11
1.9	ENOX Proteins Differ Markedly from the NOX Proteins of Host Defense	13
1.10	ENOX Proteins Are of Low Specific Activity	14
1.10.1	Natural Electron Donors and Acceptors for Cell Surface-Associated ENOX Proteins	14
1.10.2	Hydroquinones as Natural Electron Donors	15
1.10.3	Reduced Pyridine Nucleotides as Artificial Electron Donors	15
1.10.4	Protein Thiols and Tyrosines as Electron Donors for arNOX Proteins and Generation of Superoxide	15
1.10.5	Aggregation and Formation of Amyloid	16
1.11	Why an External NADH Oxidase?	17
1.12	Summary	17

2	Measurements of ECTO-NOX (ENOX) Activities	19
2.1	Spectrophotometric Assay of NADH Oxidase	21
2.2	Statistical Analysis	22
2.3	Data Reduction Methods.....	23
2.3.1	Diode Array Instruments	30
2.4	Measurement of Hydroquinone Oxidase Activity with Reduced Coenzyme Q ₁₀ or Phylloquinone as Substrate	32
2.4.1	Enzyme Assay for Reduced Coenzyme Q ₁₀ Oxidase	32
2.4.2	Enzyme Assay for Reduced Phylloquinone Oxidase	33
2.5	Dissolved Oxygen Measurement	35
2.6	Estimation of Protein Disulfide-Thiol Interchange Activity	38
2.7	Preparation of Scrambled RNase Substrate	38
2.8	Estimates of Protein Disulfide-Thiol Interchange from Enzymatic Assay of Dipyrindyl-Dithio Substrate Cleavage.....	41
2.9	Measurement of <i>Trans</i> -Plasma Membrane Redox by Reduction of Cell-Impermeable Dyes	42
2.9.1	CoQ ₁ Can Function as an Intermediate Electron Carrier in WST-1 Reduction.....	42
2.9.2	Measurement of Plasma Membrane Electron Transport Based on WST-1 Reduction.....	42
2.10	Summary	44
3	The Constitutive ENOX1 (CNOX)	47
3.1	ENOX1 Function	47
3.2	ENOX1 Cloning.....	50
3.3	ENOX1 Characterization	53
3.4	ENOX1 Activity Requires the Presence of Copper	57
3.5	Copper Binding and Site-Directed Mutagenesis of Potential Copper-Binding Sites	58
3.6	Response to Nucleotides	60
3.7	Aggregation and Electron Microscopy	61
3.8	ENOX1 Fulfills Essential Roles in Cell Enlargement and Cellular Time-Keeping.....	62
3.9	ENOX1 of Human Platelets.....	62
3.10	Summary	62
4	Role in Plasma Membrane Electron Transport	65
4.1	Composition of the PMET	65
4.1.1	NADH Coenzyme Q Reductases	66
4.1.2	Hydroquinones	68
4.1.3	Terminal Oxidases.....	69
4.2	Electron Donors and Acceptors	73
4.3	Rates of PMET.....	73
4.4	Energetics of PMET.....	76
4.5	PMET Driven Outward Proton Pumping and Alkalinization of the Cytoplasm.....	78

4.6	PMET Function in Electron Import	80
4.7	PMET and Growth	81
4.7.1	Cell Cycle Check Point Control of Cell Enlargement.....	81
4.7.2	PMET Activity and Growth Are Correlated.....	82
4.8	Regulation of PMET	82
4.8.1	Feedback Regulation of PMET	85
4.8.2	ENOX Cell Surface Receptor Proteins	86
4.9	PMET and Glycolysis	86
4.9.1	PMET and Glycolysis of Cancer Cells.....	86
4.10	PMET Links to Major Signaling Pathways	88
4.10.1	Sirtuins	89
4.10.2	Sphingolipid Rheostat	91
4.10.3	NADH Modulation of PTEN Provides Link of PMET to Ras-Raf-Mek-Erk, PI3-AKT-mTOR and NF- κ B	91
4.10.4	AMP-Activated Protein Kinase.....	93
4.10.5	Hypoxia	93
4.11	NAD ⁺ Homeostasis	95
4.12	Summary	95
5	Role in the Enlargement Phase of Cell Growth	97
5.1	Cell Enlargement Linked to ENOX Activities.....	97
5.2	ECTO NADH Oxidase of Liver Plasma Membranes Stimulated by Hormones and Growth Factors.....	98
5.3	ECTO NADH Oxidase of Rat Hepatoma Plasma Membrane Constitutively Activated and No Longer Growth Factor or Hormone-Responsive.....	98
5.3.1	Thiol Reagents.....	100
5.4	Relationship to Growth.....	101
5.4.1	Plants	101
5.4.2	Vertebrate Cells	113
5.5	Pathological Implications.....	123
5.5.1	Apoptosis.....	123
5.6	Physical Membrane Displacements	124
5.7	ATP- and p97 AAA-ATPase-Dependent and Drug-Inhibited Vesicle Enlargement Reconstituted Using Synthetic Lipids and Recombinant Proteins	124
5.8	Summary	138
6	Roles as Ultradian Oscillators of the Cells Biological Clock.....	141
6.1	Time Keeping Properties	141
6.2	Molecular Studies	142
6.3	Studies with Deuterium Oxide.....	148
6.4	The Role of Copper.....	149
6.5	The Copper Clock.....	150

6.6	EXAFS Investigations	152
6.7	Oscillations Inherent in the Structure of Water.....	154
6.8	Period Length Determined by Ionic Radius of Liganded Cation	158
6.9	Spectral Evidence for Disequilibrium of <i>ortho:para</i> Spin States in Liquid Water That Oscillate	161
6.10	Other Mechanisms Proposed for <i>ortho/para</i> Conversions and Departures from Their Equilibrium Ratio of 3:1	164
6.11	The 24-min Period Has Properties of a Carrier Wave Generated from the Basic Underlying <i>ortho-para</i> Water Oscillations? The Heart Rate Model	166
6.11.1	Growth Oscillations of Elongating Pollen Tubes	168
6.12	Phasing of the Rhythm.....	168
6.12.1	EMF Sets the Copper Clock.....	169
6.13	A Mechanism to Explain How Oscillations of Redox Potential of Aqueous Solutions Become Synchronous and Remain So	172
6.14	ENOX Clock and Cancer.....	177
6.15	Are ENOX Oscillators Linked to the Drivers of the Circadian Clock and How Are They Linked?.....	178
6.16	Why Oscillate? A Consequence of Active Sites in Metalloproteins?	184
6.17	Summary	185
7	Other Potential Functional Roles of ENOX Proteins	187
7.1	Cell Cycle Control	187
7.2	Gene Regulation.....	187
7.3	Endomembrane Function, Membrane Displacements, Vesicle Budding	188
7.3.1	Membrane Budding.....	188
7.3.2	Energy Requirements for Physical Membrane Displacement	190
7.4	Endocytosis and Autophagy.....	192
7.5	Host Defense	193
7.6	pH Control	193
7.7	Lipid Oxidation.....	195
7.7.1	arNOX Inhibitors and Prevention of Coronary Artery Disease	197
7.8	Life Extension and Calorie Restriction.....	197
7.9	Control of Apoptosis and Cell Survival.....	198
7.10	Neurodegenerative Disorders.....	200
7.11	Memory	201
7.12	Gametogenesis	202

7.13	Role in Viral Pathogenesis	203
7.13.1	ENOX2 Inhibitor (-)-Epigallocatechin-3-Gallate Blocks Virus Infections Alone and in Combination with Capsicum Vanilloids and Other Green Tea Catechins	205
7.13.2	Brefeldin A and Antitumor Quassinoids.....	207
7.14	Summary	209
8	ENOX2 (tNOX) and Cancer	211
8.1	ENOX2 Discovery	211
8.2	ENOX2 Activity.....	213
8.2.1	Biochemistry	217
8.3	Sequence	218
8.4	Structural Properties.....	222
8.4.1	ENOX2 Protein Phosphorylation	228
8.5	ENOX2 Presence and Cancer	228
8.5.1	ENOX2 Autoantibodies Generated in Cancer Patients.....	230
8.5.2	ENOX2 Gene Present in Genome as a Single Copy	230
8.5.3	ENOX2 Lacks Intrinsic Membrane-Binding Motifs.....	230
8.5.4	ENOX2 Has Properties of a Prion and Is Protease Resistant.....	231
8.6	ENOX2 Has Characteristics of an Oncofetal Protein	233
8.7	Transgenic Mouse Strain Overexpressing ENOX2	235
8.8	Alternative Splicing as Basis for Specific ENOX2 Localization to the Cell Surface.....	242
8.8.1	Full-Length ENOX2 mRNA Identical to That of Cancer Cells Exists in Human Non-cancer Cells and Tissues	247
8.8.2	Full-Length 71 kDa ENOX2 Protein Not Translated	248
8.8.3	Cancer-Specific Expression of ENOX2	250
8.8.4	Splice Variants of ENOX2 Were Found in Cancer Cells	250
8.8.5	Expression of Exon 4 Minus and Exon 5 Minus Forms of ENOX2 in COS Cells	250
8.8.6	Delivery of 34 kDa ENOX2 Protein to the Plasma Membrane	252
8.8.7	Mutation of Met 231 Blocked Expression of the Exon 4 Minus Splice Variant.....	252
8.8.8	Subcellular Localization of E4m ENOX2-EGFP and Full-Length ENOX2-EGFP Fusion Proteins	253
8.8.9	Regulation of ENOX2 Expression	256
8.9	hnRNP F Splicing Factor Directs Formation of the Exon 4 Minus Variant of ENOX2.....	257
8.10	Summary	259

9 Age-Related ENOX Proteins (arNOX)..... 261

9.1 arNOX Discovery 264

9.2 Measurement of Superoxide Formation by arNOX..... 266

9.3 Characteristics..... 268

9.4 arNOX Cloning..... 272

9.5 Characterization of Recombinant arNOX Proteins..... 279

9.6 arNOX as a Biomarker of Aging 284

9.7 Role in Skin Aging..... 286

9.8 Role in Oxidation of Serum Lipoproteins..... 291

9.9 arNOX Activity Correlates with Life Span in Sea Urchins 297

9.10 arNOX in Plants 298

9.11 arNOX Inhibitors 299

9.11.1 Coenzyme Q..... 299

9.11.2 Botanical Sources of arNOX Inhibitors 305

9.12 Beneficial Biological Function Associated with Superoxide
Production: Physiological Roles of Superoxide 307

9.13 NQO1 (Cytoplasmic NAD(P)H: Quinone Oxidoreductases,
DT-Diaphorase EC 1.6.99.2) and Plasma Membrane
Electron Transport..... 309

9.14 Summary 310

**10 The Auxin-Stimulated ENOX and Auxin Stimulation
of Plant Growth..... 313**

10.1 Early Evidence for Auxin-Modulated Enzymes Involved
in Plant Cell Enlargement 313

10.2 The Plasma Membrane as the Subcellular Location
of the Auxin-Responsive Mechanism 317

10.3 Direct Effects of Auxin on Signaling Molecules Fail
to Parallel Those of Mammalian Growth Factors..... 318

10.4 Evidence for a Redox-Related Plasma
Membrane-Located Auxin Target 321

10.4.1 Separation of Auxin-Activated and Constitutive
NADH Oxidase Activities..... 327

10.5 Auxin-Stimulated NADH Activity and Growth
Oscillates with a Period Length of 24 min..... 327

10.6 Golgi Apparatus Transport Important to Sustained
Cell Enlargement but not Specifically Required
for Auxin-Induced Cell Enlargement..... 331

10.7 Response of ENOX of Isolated Plasma Membrane
Vesicles to Osmotica 331

10.8 Inhibitors of the Auxin-Stimulated NADH Oxidase
of Plants 332

10.9 Cell Elongation Oscillates with a Period of 24 min
and Exhibits a Second set of Oscillations in Response
to 2,4-D 335

10.10	The Auxin-Stimulated ENOX Has Properties of a Prion: How 2,4-D Kills Plants	337
10.11	Summary	347
11	Cancer Therapeutic Applications of ENOX2 Proteins	345
11.1	PMET as a Target for Anticancer Drug Development	348
11.1.1	Arsenicals as Unspecific Anticancer PMET Inhibitors.....	349
11.2	Inhibition of PMET and Induction of Apoptosis	350
11.2.1	Mechanism of Induction of Apoptosis When Plasma Membrane Electron Transport Is Inhibited.....	351
11.3	Mechanism of Growth Arrest When Plasma Membrane Electron Transport Is Inhibited	355
11.3.1	Elevation of Ceramide	355
11.3.2	Links for Elevated Ceramide and Cell Cycle Arrest.....	355
11.3.3	ENOX2 Inhibitors Slow the Growth of HeLa Cells and Induce Apoptosis in Cancer But Not in Noncancer Cells	356
11.3.4	ENOX Inhibitors Increase Cytosolic NADH Levels.....	358
11.3.5	Increased NADH Resulting from ENOX2 Cell Surface Inhibition Inhibits Plasma Membrane- Associated Sphingosine Kinase (SK) and Lowers Levels of Prosurvival Sphingosine-1-Phosphate.....	359
11.3.6	Sphingomyelinase.....	359
11.4	ENOX2 Inhibitors	362
11.4.1	Vanilloids (Capsaicinoids) as PMET Inhibitors	363
11.4.2	Anthracycline Antibiotics	368
11.4.3	Cisplatin Targets ENOX2 of the PMET	377
11.4.4	Antitumor Sulfonylureas	378
11.4.5	Antitumor Quassinoids Target ENOX2.....	387
11.4.6	Acetogenins	390
11.4.7	EGCg	391
11.4.8	Phenoxodiol Targets the PMET Through Inhibition of ENOX2.....	400
11.4.9	Sulforaphane	408
11.4.10	Suramin.....	409
11.4.11	Callipeltin	409
11.5	Nonsteroidal Anti-inflammatory Drugs	410
11.6	Retinoids and Calcitriol Agents of Differentiation	411
11.6.1	Retinoic Acid Inhibition of PMET	411
11.6.2	Retinoid Inhibition of ENOX2	411
11.7	ENOX2-Directed Therapeutic Antibodies	412

- 11.8 Antisense..... 414
- 11.9 ENOX Inhibitors Enhance the Response
of Tumors to Radiation 415
- 11.10 ENOX2 as a Target for Cancer Prevention Through
Early Intervention 415
- 11.11 Summary 416
- 12 Cancer Diagnostic Applications of ENOX2 Proteins..... 419**
 - 12.1 Cancer Cell Surface ENOX2 Shed into Sera as Biomarkers
of Cancer Presence..... 420
 - 12.1.1 Biomarker Discovery Based on ENOX2 Activity..... 421
 - 12.1.2 Characteristics of ENOX2 as Cancer Biomarker
Based on Activity 421
 - 12.1.3 Transcript Variants Detected by Two-
Dimensional Gel-Western Blot Analysis
Are Cancer Site-Specific Biomarkers..... 424
 - 12.1.4 Transcript Variants of ENOX2 425
 - 12.2 Two-Dimensional Gel-Western Blot Cancer
Detection System 425
 - 12.2.1 Two-Dimensional Gel-Western Blot Analysis
of ENOX2 Transcript Variants Provide
for Very Early Detection..... 428
 - 12.3 Early Intervention 430
 - 12.4 ENOX2 Autoantibodies May Preclude Conventional
ELISA Tests for Early Appearance of ENOX2
in Serum or Plasma 430
 - 12.5 Lipid-Associated Sialic Acid (LASA) Fractions
from Sera of Cancer Patients Contain ENOX2 Fragments
as Major Nonlipid Constituents 432
 - 12.6 RTPCR Detection of Cancer Cells in Blood Based
on Presence of ENOX2 Splice Variant mRNA..... 433
 - 12.7 Summary 433
- Epilogue—Remaining Challenges 435**
- Appendix Detailed Description of Two Dimensional Gel
Electrophoresis-Western Blot Early Cancer
Detection Protocol 441**
- References..... 443**
- Index..... 493**